CClinicalTrials.gg
Status unknownNCT02549612Updated Nov 29, 2016

The Effect of Early Non-Surgical Treatment of Children With Middle Ear Effusion on the Hearing

An interventional study of Moniri Otovent in Secretory Otitis Media and Acute Otitis Media, sponsored by Vastra Gotaland Region. Status unknown. Open to participants aged 30 Months to 7 Years. Per ClinicalTrials.gov, last updated 2016-11-29.

Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2016), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
30 Months to 7 Years
Sex
All
01

Study summary

Secretory otitis media (SOM) or middle ear effusion is a common finding after acute otitis media (AOM). It is usually associated with 5-15 deci Bells hearing loss. Although spontaneous resolution with normalisation of hearing is the usual outcome, this can take several months. Secretory otitis media is the most common cause of hearing impairment in the paediatric age group. When the hearing loss caused by SOM is bilateral and persists for 3-6 months or more, surgery with tympanostomy tube insertion under general anaesthesia is indicated. In Sweden, 10000 children undergo this operation annually. Although many children with unilateral or bilateral SOM improve in the summer, the problem usually recurs in the autumn or winter. The cost of SOM for the Swedish society was 600 million Swedish crowns 2005.

In two previous studies, the investigators concluded that the nonsurgical treatment method, that was developed to assist children with SOM equalising their middle ear pressure, could normalise the hearing level in 80 % of children with SOM of minimum duration of 3 months. These children avoided therefore grommet insertion.

The investigators would like to assess the effect of this new treatment method on hearing directly after AOM. The investigators expect that using the new method could rapidly normalise hearing in these cases and thereby operation with grommet insertion could be avoided.

Read the detailed description

Background:

Secretory otitis media (SOM) or middle ear effusion is the most common cause of hearing impairment in children. Hearing loss occurs due to the accumulation of fluid in the middle ear. In most of the cases, SOM follows acute otitis media (AOM). In cases when the SOM is bilateral and persists for more than 3-6 months, operation with grommet insertion under general anaesthesia is indicated. 10000 children with SOM are operated with grommet insertion every year in Sweden. In cases of unilateral hearing loss caused by SOM, grommet insertion is rarely indicated if the duration of symptoms is less than one year. Some patients develop persistent perforation in the eardrum after extrusion of the tympanostomy tube.

A new method of middle ear pressure equalisation has been developed at the Sahlgrenska University Hospital. 45 children in the age of 2-8 years with SOM that persisted for more than 3 months had been treated with this new method under the waiting period for grommet insertion. 80% of these children had been cured with regaining of normal hearing and avoided operation. No complication/side effects were noticed and the compliance was good.

Aim of the study:

To assess the effectivity of the new nonsurgical treatment method for equalisation of middle ear pressure in rapid regaining of hearing after acute otitis media in 2,5-7 years old children.

Study design:

Quantitative

Hypothesis:

Can the new nonsurgical method rapidly normalise hearing in children with middle ear effusion/secretory otitis media after acute otitis media.

Material and Method:

80 children in the age of 2,5-7 years will be offered, directly after completed treatment of AOM, inclusion in the study. All the patients will undergo during the first visit microscopic examination of the ears, audiogram and tympanogram. The children will be randomised thereafter into two groups. The first group is treated with the new method for one week. While the other group is not actively treated and will act as a control. Both groups undergo one week after randomisation new examination with microscopic examination of the ears, audiogram and tympanogram. These examinations are repeated after one and three months.

Intervention:

The first group with verified middle ear effusion after AOM is treated with the new nonsurgical method of middle ear pressure equalisation. A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to balloon. A safety valve is used to prevent too high air pressure. A balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. On the first day, a low pressure balloon is used, then it is changed to a balloon with higher pressure. If no effect is noticed, (the child should experience clicking sound in one or both ears) on the third day, the balloon is replaced with a new balloon with additionally higher pressure. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one week.

Expected results and importance:

The investigators expect that the study will show that the new treatment method of SOM secondary to AOM can rapidly and effectively improve hearing of the affected child. This can be of great significance from medical, social and economic point of view. Hearing impairment in the paediatric age group has a great negative impact on speech development and are not only disadvantageous to the child and the parent but also for the whole society.

02

Conditions studied

  • Secretory Otitis Media
  • Acute Otitis Media

Keywords

  • Conductive hearing loss
  • middle ear pressure equalization
  • middle ear effusion
03

In context

Otitis

246 studies on the registry are indexed under Otitis; 21 are open to participants now.

This study's planned enrollment of 80 is below the median of 126 across 173 interventional studies indexed under Otitis.

Browse Otitis studies →

Lead sponsor

Vastra Gotaland Region is the lead sponsor of 267 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Months to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Unilateral or bilateral middle ear effusion with resultant conductive hearing loss one week after acute otitis media.
  • Intact tympanic membranes bilaterally.
  • Acceptable level of written and spoken swedish language skills.

Exclusion criteria

Exclusion Criteria:

  • Comorbidity,
  • Perforated acute otitis media or other complications of acute otitis media.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Moniri Otovent

    A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. On the first day, a low pressure balloon is used, then it is changed with a higher pressure balloon. If no effect is noticed, (the child should experience clicking sound in one or both ears) after day 3, the balloon is replaced with a new balloon with additionally higher pressure. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one week.

    Device: Moniri Otovent

  • No intervention
    Control

    No intervention is used in this group.

Interventions

  • DeviceMoniri Otovent

    Please see arm description.

06

What researchers measure

Primary outcomes

  1. Change from Baseline (start of treatment in the treatment group or start of control in the control group) in Hearing Level measured using age suitable audiogram.

    Measuring hearing threshold using age suitable audiogram.

    Time frame: One week after baseline.

  2. Change from Baseline (start of treatment in the treatment group or start of control in the control group) in Hearing Level measured using age suitable audiogram.

    Measuring hearing threshold using age suitable audiogram.

    Time frame: One month after baseline.

  3. Change from Baseline (start of treatment in the treatment group or start of control in the control group) in Hearing Level measured using age suitable audiogram.

    Measuring hearing threshold using age suitable audiogram.

    Time frame: Three months after baseline.

Secondary outcomes

  1. Change from Baseline in Middle Ear Pressure measured using tympanogram.

    Measuring middle ear pressure using tympanogram.

    Time frame: One week, one month and three months after baseline.

  2. Presence of Fluid in the Middle Ear.

    Microscopic examination of the tympanic membrane to show the presence or absence of fluid in the middle ear.

    Time frame: One week, one month and three months after baseline.

  3. Health Economics Measured Mainly by the Number of Parental Leave Days which the parent/parents needed to take in order to look after the child.

    Time frame: Three months after baseline.

  4. Otitis Media Questionnaire-14 (OMQ-14).

    Please see Links

    Time frame: Three months after baseline.

  5. Number of Health Care or Hospital Visits due to Ear Associated Problems.

    Time frame: Three months after baseline.

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02549612
Lead sponsor
Vastra Gotaland Region
Responsible party
Sponsor
First posted
Sep 15, 2015
Start date
Mar 2017
Primary completion
Sep 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Nov 29, 2016

Study contacts

Mohammed Al-Azzawe
Contact
mohammed.al-azzawe@vgregion.se
Hasse Ejnell
Contact
hasse.ejnell@vgregion.se
Hasse Ejnell
study director · Sahlgrenska University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion